Drug Delivery System
Online ISSN : 1881-2732
Print ISSN : 0913-5006
ISSN-L : 0913-5006
Search
Advanced search
OR
Browse
Search
Volume 29, Issue 1
By Learning the old, Finding the new of the DDS: 30-year History and Future
Displaying 1-13 of 13 articles from this issue
Show all abstracts
    • |<
    • <
    • 1
    • >
    • >|
The new year’s greetings
Feature articles " By Learning the old, Finding the new of the DDS: 30-year History and Future" Editor:Tohru Mizushima
  • [FOREWORD]By Learning the old, Finding the new of the DDS : 30-year History and Future
    Tohru Mizushima
    2014 Volume 29 Issue 1 Pages 7
    Published: January 25, 2014
    Released on J-STAGE: May 29, 2014
    DOIhttps://doi.org/10.2745/dds.29.7
    JOURNAL FREE ACCESS
    Download PDF (153K)
  • [OPINION]“Science of Science” in DDS Research
    Tsuneji Nagai
    2014 Volume 29 Issue 1 Pages 8
    Published: January 25, 2014
    Released on J-STAGE: May 29, 2014
    DOIhttps://doi.org/10.2745/dds.29.8
    JOURNAL FREE ACCESS
    Download PDF (138K)
  • The perspective of DDS from the viewpoint of a basic researcher
    Yoshinobu Takakura
    2014 Volume 29 Issue 1 Pages 30-38
    Published: January 25, 2014
    Released on J-STAGE: May 29, 2014
    DOIhttps://doi.org/10.2745/dds.29.30
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    DDS research has been developed based on the fusion of multidisciplinary basic sciences such as medical sciences, pharmaceutical sciences, engineering sciences, etc. It is expected that further fusion of sciences in different areas will be facilitated because DDS researches on a variety of novel drug candidates for gene, nucleic acid drugs, and cell therapeutics are ongoing. In this review, the history, current status and future perspective of DDS research will be discussed.
    View full abstract
    Download PDF (975K)
  • A clinical trial can determine the course of DDS development
    Yasuhiro Matsumura
    2014 Volume 29 Issue 1 Pages 39-50
    Published: January 25, 2014
    Released on J-STAGE: May 29, 2014
    DOIhttps://doi.org/10.2745/dds.29.39
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    There are two main concepts in DDS, passive targeting and active targeting. The passive targeting system is achieved by the EPR effect, that is, the enhanced permeability and retention effect. Several DDS formulations have been approved worldwide. A phase 3 trial of a micelle formulation developed for the first time in Japan is now underway. Due to the success of T-DM1 in patients with metastatic breast cancer, active targeting, or antibody-drug conjugate (ADC）, is again receiving attention in a robust fashion. but this ADC strategy should be confined to highly toxic anticancer agents but not to ordinary ACA such as taxane, adriamycin and others because only less than three ACA molecules should be conjugated to the mAb, otherwise the affinity of the mAb is diminished if too many molecules of ACA are attached to the mAb. According to this principle, unrealistic amount of ADC should be administered if the mAbs are conjugated with an ordinary ACA. Therefore, for an ordinary ACA, nanoparticles should be considered as a DDS tool.Investigators of DDS should keep in mind at an early stage of development what the target cancer is and what kind of regimen is the current standard therapy for future clinical evaluation.
    View full abstract
    Download PDF (1394K)
  • Future perspective of DDS technologies from the viewpoint of pharmaceutical companies
    Hiroshi Kikuchi
    2014 Volume 29 Issue 1 Pages 51-63
    Published: January 25, 2014
    Released on J-STAGE: May 29, 2014
    DOIhttps://doi.org/10.2745/dds.29.51
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    There are varieties of DDS (drug delivery system) technologies and a very significant number of DDS medicines already launched out in the world. It is not too much to say that DDS has established itself as one of the major tools for drug development. DDS technology has become more and more important for the pharmaceutical companies, because it is very difficult for them to discover the novel drugs these days. Each DDS technology has not only advantages but also limitations respectively based on its characteristics, so it is considered very important to understand individual DDS technology in detail for development of DDS medicines.
    View full abstract
    Download PDF (1006K)
  • DDS business from venture capital's viewpoint
    Hiroyuki Hasegawa
    2014 Volume 29 Issue 1 Pages 64-72
    Published: January 25, 2014
    Released on J-STAGE: May 29, 2014
    DOIhttps://doi.org/10.2745/dds.29.64
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    Venture capitals are investing in ventures with high growth potential providing a product and service through new technology and business model. In Japan, many ventures with a DDS (Drug delivery system) technology (DDS ventures) have established, and some of them have carried out the clinical trial of their pipeline. There are two important points in DDS ventures from my experience of an investment activity as follows. 1) For the pharmaceutical company, the attractiveness as a product itself with their DDS technology is more valuable than the superiority of their DDS technology. 2) As for the DDS ventures, the manufacturing process of materials of DDS and the bulk of products with DDS becomes the big hurdle in research and development (R&D).In a tide of the open innovation in the R&D, pharmaceutical companies have been trying to find DDS technologies in academia directly. We recognize this situation as one of the investment opportunity and will keep eyes on DDS technologies more closely.
    View full abstract
    Download PDF (645K)
  • Proposal for the Japan society of Drug Delivery System
    Kazuhiko Mori
    2014 Volume 29 Issue 1 Pages 73-76
    Published: January 25, 2014
    Released on J-STAGE: May 29, 2014
    DOIhttps://doi.org/10.2745/dds.29.73
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    The success rate has decreased to 1/30,000 or less while the cost of the new medicine development increases in recent years. To improve this situation, Pharmaceuticals and Medical Devices Agency (PMDA) has been executing Pharmaceutical Affairs Consultation on R&D Strategy since July, 2011. The personnel exchange has been begun by the budget of Ministry of Health, Labour and Welfare (MHLW) between PMDA and research laboratories since October, 2012. On the other hand, United States Food and Drug Administration (FDA) commissioner published "The Path to Personalized Medicine" in July, 2010 on the New England Journal of Medicine. Subsequently, FDA has been publishing various reports to support the practical use of innovative new drugs as regulatory authority. As for this approach of a regulator each Japan-U.S., a strategy, a personnel training, and an open innovation necessary for the innovative DDS development are expected to be promoted rapidly.
    View full abstract
    Download PDF (675K)
Front line of DDS development in pharmaceutical industries
Recent advancements in instruments used for DDS research
"Young square" (mini review)
    • |<
    • <
    • 1
    • >
    • >|
feedback
 Top